Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that because there are no therapies approved specifically for the treatment of mild cognitive impairment, off-label use of Alzheimer's disease drugs currently drives the market and will continue to dominate the market through 2016.

The new Pharmacor report entitled Mild Cognitive Impairment finds that it is the lack of regulatory approval that forces mild cognitive impairment therapeutic options to be entirely off-label.

"Off-label use restricts the number of patients who can receive such therapies, particularly in Europe where reimbursement is more tightly regulated," said Bethany Kiernan, Ph.D., analyst at Decision Resources. "As a result, drug-treatment rates for mild cognitive impairment are low. However, I expect that diagnosis and drug-treatment rates will increase significantly by 2016 because of the emergence of disease-modifying therapies for Alzheimer's disease and the launch of amyloid biomarkers."

The report also finds that treatment options for mild cognitive impairment are limited in Japan. Currently, the only therapy available for mild cognitive impairment is Eisai/Pfizer's Aricept/Bracco's Memac. This lack of therapeutic options has contributed to low drug-treatment rates in this market. However, the launches of Shire/Janssen/Ortho-McNeil Neurologics' Reminyl/ Razadyne, Novartis' Exelon/Esteve/Biofutura's Prometax, and Merz's Azura/Grupo Grunenthal's Akatinol/Lundbeck's Ebixa/Forest Laboratories' Namenda beginning in 2010 will provide additional therapeutic options to Japanese mild cognitive impairment patients and prompt modest sales growth in this market.

About Mild Cognitive Impairment

Mild cognitive impairment is a diagnosis given to individuals who have cognitive impairments beyond that expected for their age and education, but that do not interfere significantly with their daily activities. It is considered to be the boundary or transitional stage between normal aging and dementia.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall, Decision Resources, Inc., +1-781-296-2563,

Uptake of New Therapies From Bristol-Myers Squibb/Gilead, Johnson & Johnson/Tibotec, Merck, and Pfizer Will Drive Near-Term Growth in the HIV Drug Market

View Now